HOSTED BY

ELSEVIER

CrossMark

Available online at www.sciencedirect.com

ScienceDirect

Osteoporosis and Sarcopenia 2 (2016) 89–93

http://www.elsevier.com/locate/afos

Original article

Effect of multivitamin on serum 25-hydroxy vitamin D level in postmenopausal women: A randomized, double-blind, placebo-controlled trial

Dithawut Khrutmuang*, Krasean Panyakhamlerd, Sukanya Chatkittisilpa, Unnop Jaisamrarn, Nimit Taechakraichana

Reproductive Medicine Division, Department of Obstetrics-Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10300, Thailand

Received 28 March 2016; revised 25 April 2016; accepted 25 April 2016
Available online 21 May 2016

Abstract

Objectives: To determine the effects of multivitamin vitamin D 300 or 600 units on serum 25 hydroxyvitamin D (25(OH)D) level after 4 weeks of supplementation in postmenopausal women with vitamin D insufficiency.
Study design: Randomized double-blind, placebo-controlled trial.
Methods: Postmenopausal women who had vitamin D insufficiency were recruited into the study. The participants were randomized to 3 groups of 4-week treatment period with multivitamin (GPO, Governmental Pharmacy Organization) 2 tablets (contained vitamin D2 amount 600 units), multivitamin 1 tablet (contained vitamin D2 amount 300 units) or placebo. At baseline and after 4 weeks of supplementation, serum 25(OH)D were determined with electrochemilumines-cence immunoassay (Cobas, Roche Diagnostics) and level change of 25(OH)D level were compared among the groups.
Results: Out of 144 participants, 49.3% had vitamin D deficiency (<20 ng/ml) and 50.7% had vitamin D insufficiency (<30 ng/ml). However, after 4 weeks of the GPO oral multivitamin, serum 25(OH)D levels significantly increased from 19.4 ± 6.3 ng/ml at baseline to 22.2 ± 5.2 ng/ml ($p = 0.01$) and from 19.5 ± 5.0 ng/ml to 23.3 ± 5.2 ng/ml ($p < 0.01$) in the groups receiving vitamin D 300 IU and 600 IU/day, respectively. Approximately, 10% of those who took vitamin D had serum 25(OH)D level above the insufficiency level within 4 weeks. There was no significant changes of serum 25(OH)D after 4 weeks in the placebo group.
Conclusions: Daily supplementation of the generic multivitamin containing vitamin D2 300 and 600 IU daily for 4 weeks significantly increased mean serum 25(OH)D from baseline up above the deficiency level.

Keywords: Postmenopause; Multivitamin; Vitamin D insufficiency; Serum total 25 hydroxyvitamin D

1. Introduction

Vitamin D deficiency is defined as a 25-hydroxyvitamin D (25(OH)D) level < 20 ng/ml (50 nmol/L) and vitamin D insufficiency as a 25(OH)D < 30 ng/ml (75 nmol/L) [1]. Vitamin D deficiency is associated with low bone mass and osteoporotic fractures [2]. Nonetheless, vitamin D insufficiency is associated with rising PTH when the level is below 30 ng/ml [1,3]. Vitamin D insufficiency is believed to be common in postmenopausal women [4]. A survey in Thailand, using the cutoff value of 25(OH)D ≤ 35 ng/ml, found that 77.81% of Thai premenopausal women were considered to have vitamin D insufficiency [5].

In 2011, the Endocrine Society Task Force's published guideline for evaluation, treatment, and prevention of vitamin

Thai clinical trials registration: URL: http://www.clinicaltrials.in.th. Identification number: TCTR20131206001.

* Corresponding author. Reproductive Medicine Division, Department of Obstetrics-Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10300, Thailand.
E-mail address: dithawut@hotmail.com (D. Khrutmuang).

Peer review under responsibility of The Korean Society of Osteoporosis.

http://dx.doi.org/10.1016/j.afos.2016.04.003

D deficiency suggested that all adults age 50–70 and 70 + years require at least 600 and 800 IU/day of inactive vitamin D, respectively to maximize bone health. However, to raise the blood level of 25(OH)D above 30 ng/ml may require at least 1500–2000 IU/day [1].

Although it is still unclear whether we need such high doses of vitamin D, a meta-analysis revealed that vitamin D supplement at the dose of 700–800 IU/day was associated with reduction of hip and non-vertebral fractures in older persons [6].

With the dilemma of which to treat between "vitamin D deficiency" and "vitamin D insufficiency" which may have great impact on health expenditure, we are interested to study the changes of 25(OH)D level after ingestion of a daily dose of either 300 or 600 IU of an inactive vitamin D containing in a generic oral multivitamin (Governmental Pharmacy Organization, GPO) for 4 weeks. The GPO multivitamin is cheap and locally produced within the country. Oral multivitamin has been recommended and prescribed arbitrarily in clinical practice as a supplementation to prevent vitamin D deficiency and insufficiency which were claimed to have high prevalence among Thai postmenopausal women. To address this issue, we conducted a randomized, double-blind, placebo-controlled trial to assess serum levels of 25(OH)D in 3 groups of participants who were blinded to receive a daily dose of placebo or multivitamin containing 300 IU or 600 IU of vitamin D.

2. Material and methods

This study was a randomized, double-blind, placebo-controlled trial conducted from August 2012 to January 2013 at the Menopause Clinic, King Chulalongkorn Memorial Hospital. The study has been approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn Univesity and was conducted in accordance with the Declaration of Helsinki of Good Clinical Practice. The trial is registered at Thai Clinical Trials Registration (TCTR20131206001). All women provided their written, informed consent before recruitment and had the right to withdraw from the study at any time. Participants could also be withdrawn from the study at the discretion of the investigators at any time.

Participants who were included into the study were Thai postmenopausal women, aged between 50 and 80 years, ambulatory, community-dwellers, body mass index between 18.50–25.00 kg/m^2, having serum 25(OH)D < 30 ng/ml and were willing to participate in the study. Participants were excluded if they were women who used vitamin D-contained medicine within 12 weeks, having a history of malignancy, liver disease, renal disease, hyperparathyroidism disorder, malabsorption, bowel surgery or having abnormal liver or renal function test.

In this study, we define postmenopausal women as those ≥50 years who had permanent cessation of menstruation for at least one year or women who underwent bilateral oophorectomy. Vitamin D insufficiency is defined as a serum 25(OH)D < 30 ng/ml (75 nmol/L) [1]; Vitamin D deficiency: defined as a serum 25(OH)D < 20 ng/ml (50 nmol/L) [1].

Oral multivitamin (GPO®)contained of Vitamin D2 of 300 IU, nicotinamide 7.5 mg, vitamin B2 0.5 mg, vitamin B1 1 mg, vitamin A 2500 IU and vitamin C 15 mg. Independent pharmacist dispensed either pre-packed oral multivitamin 1 tablet (Vitamin D2 300) in one opaque capsule or oral multivitamin (GPO®) 2 tablets in one opaque capsule or placebo used of folic acid (5 mg) (GPO®) 1 tablet in one opaque capsule according to the block of three randomization list.

The multivitamin one tablet, two tablets and placebo were in packages that were identical in appearance. They were packed in one opaque capsule in opaque envelops and consecutively numbered for each women according to the randomization schedule. Each woman was assigned an order number and received the capsules in the corresponding pre-packed envelop.

The serum 25(OH)D, serum creatinine, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase level were assessed at baseline. Serum 25(OH)D was measured by electrochemiluminescence immunoassay (Cobas, Roche Diagnostics Thailand). The inter-assay and intra-assay coefficients of variation (CV) of 25(OH)D were 3.52% and 1.53%, respectively. All analytical platforms and immunoassays were used in the laboratory for routine testing and were strictly run in accordance with the manufacturers' guidelines and according to the laboratories' standard operating procedures (SOP) for good laboratory practice.

During the "screening and baseline visit (first visit)", all participants were interviewed and underwent general physical examination. Baseline characteristics were recorded in the case record form. Blood was drawn between 8:00 and 9:30 a.m. after the subjects had fasted for at least 8 h. These were either analyzed immediately or stored at −20 °C until analyzed. Women with baseline serum 25(OH)D level < 30 ng/ml were enrolled into the study. All participants were explained to take a drug for one capsule at 8.00 p.m. for 28 days. The administration of drug was recorded by patients' self-report on daily record form.

On the follow-up visit (week 2), all participants were interviewed by phone after 2 weeks of drug administration to assess the treatment compliance and adverse effects. On the 3rd visit (week 4), serum 25(OH)D was measured after 28 days of supplement. Blood were collected within 3 days after the last pill intake. Blood were collected and sent to the central laboratory of King Chulalongkorn Memorial Hospital for the preparation of serum. The serum samples were either analyzed immediately or stored at −20 °C until analyzed for 25(OH)D level.

Participants' baseline characteristic data such as age, body mass index (BMI), year since menopause, sun-exposure time, the use of sun screen and baseline serum 25(OH)D level and all relevant laboratory data such as serum 25(OH)D, Serum glutamic oxaloacetic transaminase (SGOT), Serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase (ALP), creatinine were obtained. Post-supplement serum 25(OH)D level and change of serum 25(OH)D level were the primary outcome measurement.

Sample size was estimated based on a pilot study. A level of statistical significance of 0.05% and power of study of 90%, we